Patients with obesity or overweight and T2D saw substantially greater mean weight loss and HbA1c improvement with petrelintide versus placebo.
Opinion|Podcasts|June 3, 2024
Fostering Next-Generation Expertise in Dry Eye Treatment
Listen
0:00 / 0:00
Experts discuss strategies for making dry eye care an appealing practice option for optometry students and supporting their success in this specialized field.
Advertisement
1:29 Evolution of Dry Eye Care
5:45 Diagnostic Shifts
8:50 Resources for Students
14:00 Proactive Dry Eye Care
19:50 Starting a Dry Eye Program
25:10 Treatment Approach
Advertisement
Related to this article
Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.
Presented at EASD 2026, the present analysis discusses CBL-514’s apparent efficacy in reducing L2-L3 visceral fat compared to placebo.
A hepatologist on the lag between drinking and liver disease, metabolic risk, prevention gaps, and when the burden may peak.
Nephrology in Q3 2026: FDA approvals for atacicept, iptacopan, finerenone, and obinutuzumab, plus 2-year IgAN data and CKD screening.
Q3 2026 dermatology recap: FDA approvals in dermatomyositis, adolescent alopecia areata, and sBCC, plus new psoriasis and vitiligo findings.
Approved US PFIC drugs treat pruritus. The researcher behind a therapy targeting BSEP on diagnosis, data, and what comes next.
Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.
Advertisement
Advertisement
Trending on HCPLive
1
RELIEVE-AD-PEDs: Dupilumab Sustains Adolescent Atopic Dermatitis Control at 1 Year
2
Targeting the Disease Mechanism in PFIC, With Hisamitsu Hayashi, PhD
3
10 Nephrology Headlines You Missed in Q3 2026
4
Top Reason for Leaving HAE Attacks Untreated, Survey Finds
5